Electromed, Inc. (ELMD) 股票分析

公司概述

Electromed, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry, where it develops, manufactures, markets, and sells airway clearance therapy systems utilizing high frequency chest wall oscillation for pulmonary care. The company's primary product offering is the SmartVest airway clearance system, which is deployed to treat patients in both the United States and international markets. As of the latest data, the firm employs 177 individuals and holds a total market capitalization of $203.59 million. With reported annual revenue of $68.86 million, the company's valuation suggests it operates as a mid-cap entity with a specialized focus on a niche medical technology segment rather than a broad-market conglomerate.

财务健康

The company reported a trailing twelve-month revenue of $68.86 million and a net income of $8.99 million, resulting in an EBITDA of $12.88 million. The significant gap between revenue and net income, where costs consumed approximately 86.9% of top-line sales, reveals a cost structure that includes substantial operating expenses despite high gross profitability. Free cash flow stood at $7.08 million, indicating that the business generates sufficient cash from operations to cover capital expenditures and maintain financial flexibility for strategic initiatives. The gross margin is reported at 78.2%, which reflects the high-margin nature of medical device manufacturing and the company's pricing power in its specific therapeutic niche. Operating margin stands at 19.2%, while profit margin is 13.1%; these figures indicate that while the company manages operational overhead efficiently, a significant portion of gross profit is absorbed by general and administrative costs. The firm holds $13.79 million in cash against a debt obligation of $96,000, resulting in a debt-to-equity ratio of 0.21. This stark disparity between liquid assets and liabilities demonstrates a highly conservative balance sheet with minimal leverage. Furthermore, the current ratio of 4.86 suggests that the company possesses more than four times the current assets needed to cover its short-term liabilities, pointing to robust short-term liquidity. Return on equity is 20.2% and return on assets is 13.6%, metrics that reveal management is effectively utilizing shareholder capital and asset base to generate returns above the cost of capital.

估值评估

The trailing twelve-month P/E ratio is 23.70, whereas the forward P/E ratio is 40.02, implying that the market expects earnings growth that will eventually justify the higher multiple, though the current price implies a significant expansion in profitability relative to today's earnings. The price-to-book ratio is 4.45, indicating that the market values the company at a substantial premium over its book value, likely reflecting the intangible value of intellectual property and future growth prospects inherent in the medical device sector. Alternative valuation metrics such as a price-to-sales ratio of 2.96 and an EV/EBITDA of 14.62 provide additional context, suggesting the stock is valued roughly three times its revenue and with an earnings multiple that is elevated relative to traditional manufacturing peers. The stock has traded between a 52-week high of $30.73 and a 52-week low of $17.73. Without a specific current share price provided in the facts to calculate the exact percentage, the price metrics define the trading range within which the asset has fluctuated over the past year. The beta value is 0.32, which indicates that the stock's price volatility is significantly lower than the broader market, suggesting it may serve as a defensive holding within a healthcare portfolio during periods of market turbulence.

Growth & Income

Revenue growth year-over-year is 16.3%, while earnings growth year-over-year is 45.5%. The fact that earnings are growing at nearly three times the rate of revenue implies that the company is benefiting from operating leverage, likely due to fixed costs being spread over a larger revenue base or pricing increases on its SmartVest system. As the dividend yield is N/A and the payout ratio is 0.0%, the company does not currently distribute dividends to shareholders. Instead, the firm reinvests its entire earnings back into the business to fund research, development, and market expansion rather than providing immediate income returns. This strategy is common for medical device companies in the growth phase that prioritize capital allocation toward R&D and market penetration over shareholder payouts. Overall, the growth and income profile is characterized by strong earnings acceleration without current dividend support, positioning the asset for capital appreciation through business expansion rather than income generation.